Andexanet alfa 在侵入性或手术操作前逆转阿哌沙班与利伐沙班的效果
86.4%可评估止血效果者中78.9%达到优良止血,但30天死亡率和血栓缺血事件分别达34.1%和27.3%。
要点
- 围术期使用andexanet alfa逆转阿哌沙班或利伐沙班,78.9%可评估患者达到优良止血。
- 颅内与颅外事件止血优良率相近(80.0% vs 78.3%)。
- 30天死亡率34.1%、血栓缺血事件27.3%,需关注安全性。
核心结论
- Andexanet alfa可用于围术期紧急或急诊逆转阿哌沙班和利伐沙班,止血结局较好。
- 仍需进一步前瞻性对照临床研究验证。
主要发现
- 逆转指征为颅内20例(45.5%)、颅外24例(54.5%)。
- 阿哌沙班组优良止血19例(82.6%),利伐沙班组11例(78.6%);颅内事件12例(80.0%),颅外事件18例(78.3%)。
- 30天死亡15例(34.1%),30天血栓缺血事件12例(27.3%);出院去向以短期或长期护理机构为主(27例,61.4%)。
关键数值与推荐
- 止血效果按类似ANNEXA-4标准分为优良、良好或差。
- 给药后凝血酶原时间和抗Xa因子检测结果显著下降(p < 0.05)。
- 血栓弹力图参数(反应时间、动力学时间、活化凝血时间)逆转前后无显著变化。
临床怎么用
- 对于需紧急或急诊侵入性/手术操作的阿哌沙班或利伐沙班抗凝患者,可考虑围术期使用andexanet alfa逆转。
- 应用时需权衡较好止血效果与较高的30天死亡率和血栓缺血事件风险。
局限性
- 缺乏对照组,无法进行疗效比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Outcomes following andexanet alfa reversal of factor Xa inhibitors in patients requiring urgent or emergent invasive procedures are lacking. This study aimed to describe efficacy and safety outcomes following andexanet alfa administration within 24 h of an invasive procedure. METHODS: This single-center, observational, retrospective study included patients who received andexanet alfa within 24 h of an invasive or surgical procedure. The primary outcome was hemostatic efficacy graded as excellent, good, or poor using similar definitions to the ANNEXA-4 criteria. Secondary outcomes included hospital discharge disposition, intensive care unit (ICU) and hospital length of stay, 30-day mortality, 30-day thromboischemic event rates, and serum coagulation assay changes pre- and postreversal. RESULTS: Forty-four patients met inclusion criteria; of these, 27 (62.8%) received apixaban and 16 (37.2%) were treated with rivaroxaban prior to admission. The indications for reversal were categorized as intracranial (n = 20 [45.5%]) or extracranial (n = 24 [54.5%]) sites. Majority of patients required emergent operative procedures (18 [40.9%]), followed by invasive device placement (10 [22.7%]) or arterial embolization (9 [20.5%]). Thirty-eight (86.4%) patients were able to be adequately graded for hemostatic efficacy. Overall, 30 (78.9%) patients achieved excellent or good hemostasis within 24 h after periprocedural administration of andexanet alfa (19 [82.6%] apixaban vs. 11 [78.6%] rivaroxaban; 12 [80.0%] intracranial events vs. 18 [78.3%] extracranial events). Discharge disposition was most often to a short- or long-term care facilities (27 [61.4%]). Thirty-day mortality and thromboischemic complications occurred in 15 (34.1%) and 12 (27.3%) patients, respectively. Prothrombin time and antifactor Xa assay results were significantly decreased after andexanet alfa administration (p < 0.05) while thromboelastogram assay values (reaction time, kinetic time, and activated clotting time) showed nonsignificant changes pre- versus postreversal. CONCLUSION: Andexanet alfa may be used for urgent or emergent reversal of apixaban and rivaroxaban peri-procedurally with promising hemostatic outcomes. Further prospective, comparative clinical research is warranted.
引用
- Bradshaw PG, Keegan SP, Droege ME, et al. Reversal of apixaban and rivaroxaban with andexanet alfa prior to invasive or surgical procedures. Pharmacotherapy. 2022. PMID: 36073083. doi:10.1002/phar.2727
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。